EN | UA
EN | UA

Help Support

Back

Long-term cenobamate retention indicated tolerability and sustained clinical efficacy in seizure patients

Long-term cenobamate retention indicated tolerability and sustained clinical efficacy in seizure patients Long-term cenobamate retention indicated tolerability and sustained clinical efficacy in seizure patients
Long-term cenobamate retention indicated tolerability and sustained clinical efficacy in seizure patients Long-term cenobamate retention indicated tolerability and sustained clinical efficacy in seizure patients

What's new?

Cenobamate estimated retention rates were 80% at 1 year and 72% at 2 years in adults with drug-resistant focal seizures/epilepsy. 

In people suffering from uncontrolled focal seizures, the consistently high retention rates of cenobamate therapy revealed it to be an efficacious and well-tolerated novel treatment choice for the management of seizures. In this study, the researchers revealed pooled exposure, safety data, and retention rates from a large population with seizure that was given open-label adjunctive cenobamate therapy in the clinical development program.

Pooling of data was done from 2 randomized, controlled cenobamate studies and 1 open-label pharmacokinetic and safety study. Considering the percentage of people remaining on therapy, an estimation of retention rates was done with the aid of Kaplan-Meier survival analyses. The researchers carried out 2 additional assessments for exploring the factors contributing to retention.

A robust data set (through two years) was stratified by cenobamate modal dose and the frequently utilized concomitant anti-seizure medicines. Treatment-emergent noxious events and cenobamate discontinuations were enumerated. Data from 1844 people were pooled: (i) 355 from a multi-dose randomized trial, (ii) 149 from a single-dose randomized trial, and (iii) 1340 from an open-label pharmacokinetic and safety study.

The majority of the people from randomized trials continued in open-label extensions. The pooled data represented >95% of people exposed to cenobamate therapy. The baseline characteristics and disease and therapy histories were similar across studies. The median duration of cenobamate exposure was thirty-four months, with a median modal dose of 200 mg/day.

 

The Kaplan-Meier estimates of cumulative cenobamate retention rates at one year and two years is shown in Table 1:

Once the recruited people achieved the maintenance phase, the retention rates were consistently high in people receiving ≥100 mg/day cenobamate. The concomitant anti-seizure medicines did not impact long-term retention. Notably, 535 (29%) had actually discontinued cenobamate by two years.

Withdrawal of consent (21.1%), adverse events (37.6%), and others (16.8%) were the most commonly noted reasons for cenobamate discontinuation. Thus, the treatment retention rates offered real-world, practical evidence for long-term safety, effectiveness, adherence, and tolerability.

Source:

Epilepsia

Article:

Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program

Authors:

Josemir W Sander et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies ru en
Try: